UK Markets open in 3 hrs 28 mins

Anemia Treatment Market Report Up to 2031: Visiongain Research Inc

·5-min read

Visiongain has published a new report on Anemia Treatment Market Report to 2031: Forecasts By Anemia Type (Iron Deficiency Anemia, Hemolytic Anemia, Sickle Cell Anemia, Pernicious Anemia, and Thalassemia Anemia), By Drug Type (Bone Marrow Stimulants, Gene Therapy, Iron Chelating Agents, Corticosteroids, Supplements, and Immunotherapy), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) PLUS COVID-19 Recovery Scenarios.

Download Exclusive Sample of Report @

COVID-19 Impact on Anemia Market

The COVID-19 pandemic has deleteriously affected all the countries and industries. Similarly, the acute anemia market is anticipated to take a hit. The target industry is now facing challenges to manage the interrupted demand and supply of components. Also, unpredictable and disturbing supply chain activities and the unavailability of human resources are anticipated to impact the target industry growth. In contrast, the rising research & development activities for developing novel treatments against COVID-19 is creating a lucrative opportunity for the companies. Hence, the overall COVID-19 impact is expected to continue to moderate for the global key players operating in the industry.

Market Drivers

Growing Iron Deficiency Rate Among Population

According to the World Health Organization, nearly 56% of individuals were affected by anemia in 2018 globally. Anemia can be successfully cured with appropriate treatments. Nutritional deficiency is among the population is the key factor driving the global anemia treatment market. As per the WHO, approximately 50% of anemic cases are triggered by iron deficiency owing to the low iron consumption. Rising baby thriving population and growing chronic disorders are boosting the growth of the global anemia treatment market. An inappropriate dietary intake in low-and-middle-income countries also further propelling the target industry.

According to the World Bank, it is the 8th prominent illness affecting young girls and women. Numerous government initiatives for refining the healthcare infrastructure in emerging countries are also projected to fuel the anemia treatment market in the given assessed period. The constant research & development activities associated with anemia drugs and growing awareness about anemia in emerging and undeveloped countries are creating lucrative opportunities for the anemia treatment market shortly.

Rising Cases of Sickle-cell Anemia

Growing cases of sickle cell anemia in the underdeveloped economies are adding further demand for the anemia treatment. Besides, the accessibility of high unmet requirements, the growing drug pipeline to treat sickle cell anemia is anticipated to generate high demand for these treatments. increasing governments and regulatory bodies' support in the research & development venture, fast track endorsement for newer treatments for this disorder is further fueling the target industry growth.

Download Exclusive Sample of Report @

Market Opportunities

Potential Market Growth in Emerging Countries

More than 50% of women at pregnancy age in India and other developing countries suffer from anemia. Anemia is related to a major risk of maternal deaths, premature delivery, and increased tiredness, which disturbs the productivity of women's work. The World Health Organization (WHO) suggested regular oral administration of folic acid (IFA) and iron throughout pregnancy and weekly administration of dietary supplementation for females of childbearing age. For over four decades, government programs and NGOs have distributed and encouraged IFA supplements in India and in several other countries that are engaged globally to protect females from iron deficiency anemia.

Competitive Landscape

Key players operating in the global Anemia market are ViforPharma Ltd., Sanofi, Novartis AG, ABBVIE INC., Lupin, Akebia Therapeutics, INC., AMAG Pharmaceuticals, Fresenius SE & CO. KGAA, CHO-A Pharmaceutical CO., LTD., Orion Corporation, Shield Therapeutics, Pharmacosmos A/S, Teva Pharmaceutical Industries LTD., Advanz Pharmaceutical, Zydus Cadila, Rockwell Medical, Alkem Labs, Hikma Pharmaceuticals PLC, GlaxoSmithKline plc., and Avion Pharmaceuticals, LLC.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

To access the data contained in this document please email

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Anaemia Treatment market and leading companies. You will find data, trends and predictions.

Find more Visiongain research reports on Therapeutic Drug Sector; click on the following links:

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help:

About Visiongain

Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports mean that you can have a bespoke piece of market intelligence customized to your very own business needs.


Catherine Walker
PR at Visiongain Inc.
Tel: + 44 0207 336 6100
USA Tel: + 1 718 682 4567
EU Tel: + 353 1 695 0006
Toll Free: 00-1-646-396-5129
Follow Us: LinkedIn | Twitter


SOURCE Visiongain Limited.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting